• Recruiting

NCT04843579: Phase 2: Selinexor in Combination With Clarithromycin, Pom & Dex RRMM - ClaSPd

ClaSPd


NCT04843579: Phase 2: Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients (ClaSPd)


ClaSPd

NCT04843579: Phase 2: Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients (ClaSPd)


The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for patients with relapsed/refractory multiple myeloma. The hypothesis is that the addition of Selinexor to Clarithromycin, Pomalidomide and Dexamethasone will increase the overall response rate of patients with relapsed/refractory multiple myeloma.


Sponsor

Weill Medical College of Cornell University


Collaborator

Karyopharm Therapeutics Inc

 

ClinicalTrials.gov Identifier: NCT04843579


Official Title: A Phase 2, Open-Label, Single-Arm Study of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

First Posted : April 13, 2021


Click here for ClinicalTrials.gov

 

Selinexor : National Cancer Institute

Selinexor : MedlinePlus Drug Information

 

Drug: Selinexor

Drug: Clarithromycin

Drug: Pomalidomide

Drug: Dexamethasone

 

Locations

United States, New York

Posts Archive